Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPILOGUE phase I/II umbrella trial in relapsed or refractory pediatric low-grade glioma
2024-516896-34-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of tovorafenib, ulixertinib and vinblastine in childhood low-grade glioma (pLGG) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Dose-limiting toxicity and Best response. Planned start Jun 2026; status: authorised.
02
Drugs
tovorafenibulixertinibvinblastine
03
Conditions
childhood low-grade glioma (pLGG)
Beyond the preview
Go deeper on 2024-516896-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516896-34-00.